- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
Key statistics
As of last trade, Lexaria Bioscience Corp (LEXX:NAQ) traded at 3.13, 382.43% above the 52 week low of 0.6488 set on Jun 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.50 |
---|---|
High | 3.53 |
Low | 2.95 |
Bid | 3.11 |
Offer | 3.17 |
Previous close | 3.49 |
Average volume | 175.48k |
---|---|
Shares outstanding | 12.89m |
Free float | 11.24m |
P/E (TTM) | -- |
Market cap | 44.97m USD |
EPS (TTM) | -0.6851 USD |
Data delayed at least 15 minutes, as of May 02 2024 17:19 BST.
More ▼